XELJANZ MILESTONES IN RHEUMATOLOGY
In 2012, XELJANZ was approved to treat adults with moderate to severe rheumatoid arthritis. In 2017, XELJANZ was approved to treat adults with active psoriatic arthritis.
See how XELJANZ has evolved through the years.
1994
Pfizer identifies Janus kinase (JAK) enzymes as potential drug targets
2002
First clinical trial with humans launches clinical-development program
2012
XELJANZ, a twice-daily pill, is approved for adults with moderate to severe rheumatoid arthritis*
2016
XELJANZ XR, a once-daily pill, becomes available
2017
XELJANZ and XELJANZ XR are approved for adults with active psoriatic arthritis*
2018
XELJANZ is approved for adults with moderate to severe ulcerative colitis*
2019
XELJANZ XR is approved for adults with moderate to severe ulcerative colitis*
2020
XELJANZ and XELJANZ Oral Solution are approved for the treatment of active polyarticular course juvenile idiopathic arthritis in patients 2 and older*†
2021
XELJANZ and XELJANZ XR are approved for adults with active ankylosing spondylitis
*Indication revised to use in patients who have not responded or cannot tolerate one or more TNF blockers.
†XELJANZ XR is not interchangeable with XELJANZ Oral Solution.